EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic

Zuzana Bielcikova iD, Milos Holanek, Iveta Selingerova, Ondrej Sorejs, Iveta Kolarova, Renata Soumarova, Jan Proks, Lucie Reifova, Vlastimila Cmejlova, Lenka Linkova, Michaela Zabojnikova, Martina Chodacka und 5 weitere

The Oncologist · 2024

DOI: 10.1093/oncolo/oyae031 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2024. Verfasst von Zuzana Bielcikova und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic. Hauptthemen laut MEDLINE: Breast Neoplasms, Male. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health of the Czech Republic-conceptual development of research organization, Ministry of Health of the Czech Republic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Male breast cancer (MBC) is a rare, but increasingly common disease, and lacks prospective studies. Collaborative efforts are needed to understand and address MBC, including its prognosis, in different countries.

Methods

We retrospectively reviewed the clinical, histopathological, and molecular-genetic characteristics, treatments, and survival outcomes of MBC diagnosed between 2007 and 2017 in the Czech Republic. Prognostic factors of overall survival (OS), recurrence-free interval (RFi), and breast cancer-specific mortality (BCSM) were analyzed and indirectly compared to international data.

Results

We analyzed 256 patients with MBC (median age 66 years), including 12% with de novo metastatic (M1). Of 201 non-metastatic (M0) patients, 6% were <40 years old, 29% had stage I, 55% were cN0, and 54% underwent genetic testing. Overall, 97% of tumors had estrogen receptor expression ≥10%, 61% had high Ki67 index, 40% were high-grade (G3), and 68% were luminal B-like (HER2-negative). Systemic therapies included endocrine therapy (90%) and chemotherapy (53%). Few (5%) patients discontinued adjuvant endocrine therapy for reasons other than disease relapse or death. Patients treated with aromatase inhibitors alone had significantly shorter RFi (P < .001). OS, RFi, and BCSM were associated with disease stage, T stage, N stage, progesterone receptor expression, grade, and Ki67 index. Median OS reached 122 and 42 months in M0 and de novo M1 patients, respectively.

Conclusion

Due to the rarity of MBC, this study highlights important findings from real clinical practice. Although the number of patients with MBC with unfavorable features was higher in this Czech dataset than in international studies, the prognosis remains consistent with real-world evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast Neoplasms, MaleHumansMaleRetrospective StudiesAgedPrognosisCzech RepublicMiddle AgedAdultAged, 80 and over

Stichwörter der Autor:innen

epidemiologygenetic testingmale breast cancerprognosisretrospective study

Autor:innen und Institutionen

  • Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic.
  • Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Department of Mathematics and Statistics, Faculty of Science, Masaryk University, Brno, Czech Republic.
  • Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.

ORCID-Profile: Zuzana Bielcikova

Förderung

  • Ministry of Health of the Czech Republic-conceptual development of research organization
  • Ministry of Health of the Czech Republic

Zitieren

APA

Bielcikova, Z., Holanek, M., Selingerova, I., Sorejs, O., Kolarova, I., Soumarova, R., Proks, J., Reifova, L., Cmejlova, V., Linkova, L., Zabojnikova, M., Chodacka, M., Janovska, L., Lisnerova, L., Kasparova, K., Pohankova, D., & Petruzelka, L. (2024). Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic. The Oncologist. https://doi.org/10.1093/oncolo/oyae031

Vancouver

Bielcikova Z, Holanek M, Selingerova I, Sorejs O, Kolarova I, Soumarova R, et al. Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic. The Oncologist. 2024. doi:10.1093/oncolo/oyae031

BibTeX
@article{Bielcikova2024,
  author = {Bielcikova, Zuzana and Holanek, Milos and Selingerova, Iveta and Sorejs, Ondrej and Kolarova, Iveta and Soumarova, Renata and Proks, Jan and Reifova, Lucie and Cmejlova, Vlastimila and Linkova, Lenka and Zabojnikova, Michaela and Chodacka, Martina and Janovska, Lucie and Lisnerova, Lenka and Kasparova, Karolina and Pohankova, Denisa and Petruzelka, Lubos},
  title = {Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyae031}
}
Kostenlos starten →